Alere's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Despite the fourth quarter challenges in Europe, sales in the Asia Pacific region continued to accelerate supported by substantial growth in our high-margin cardiology and infectious disease products. As was the case in Q3, sales in Japan was strong in the fourth quarter with the revenues continuing to rebound from the effects of the earlier problems in that country, supported as well as the impact of an expanded sales force supporting the numerous cardiology products, which were approved recently in Japan.
Through the full year of 2011, we achieved new product sales of $39 million, with $13 million of those occurring in the fourth quarter. The improvement in new product revenue performance in Q4 was driven by increases in sales related to our CD4 Analyzer as well as our blood gas and electrolyte system. These important platforms are achieving increased medical adoption, and this is a key factor behind our belief that new product sales will increasingly contribute to our expanding organic growth rate over the next several years despite any short-term fluctuations associated with economic issues in various countries.
Read the rest of this transcript for free on seekingalpha.com
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
